Niagen Bioscience (NAGE) Finished Goods (2018 - 2019)
Niagen Bioscience (NAGE) posted quarterly Finished Goods of $4.9 million for Q4 2019, up 99.06% year-over-year from $2.4 million in Q4 2018, and up 99.06% quarter-over-quarter from $2.4 million in Q4 2018.
Niagen Bioscience (NAGE) Finished Goods (2018 - 2019) Analysis & Trends
Niagen Bioscience (NAGE) has reported Finished Goods for 2 consecutive years, with $4.9 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Finished Goods rose 99.06% year-over-year to $4.9 million; the TTM figure through Dec 2019 stood at $4.9 million (up 99.06% YoY), while the FY2019 annual figure was $4.9 million, up 99.06% from the prior year.
- Finished Goods rose to $4.9 million in Q4 2019 per NAGE's latest filing, from $2.4 million in the prior quarter.
- Across five years, Finished Goods topped out at $4.9 million in Q4 2019 and bottomed at $2.4 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 4.88 Mn |
| Dec 31, 2018 | 2.45 Mn |